Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yuling Shi
INTRODUCTION: Ixekizumab, a monoclonal antibody against interleukin-17A, demonstrated effectiveness in the treatment of psoriasis in a Chinese real-world study that was consistent with previous randomized controlled trials. Here, we report further analyses from this study to explore the effectiveness of ixekizumab for treating patients with psoriasis and the involvement of special body areas (scalp, nail, joint, palmoplantar, or genital areas). METHODS: A multicenter, prospective, observational, single-arm, post-marketing surveillance study was conducted in patients aged ≥ 18 years with moderate-to-severe plaque psoriasis and prescribed with ixekizumab in 26 Chinese hospitals...
March 27, 2024: Dermatology and Therapy